Twist Bioscience Corp

CRISPR Therapeutics

Recursion Pharmaceuticals

CareDx

Adaptive Biotechnologies

Veracyte

Ionis Pharma

Nurix Therapeutics, Inc

Beam Therapeutics

Intellia Therapeutics

ARK Genomic Revolution Multi-Sector ETF

ARKG is an actively managed fund that targets companies involved in the genomics industry.

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is one of the best-performing healthcare ETFs of any stripe over the past several years for a simple reason: the ability of the fund’s managers to identify companies that are breaking new ground in the rapidly evolving genomics arena. That tradition continues today.

An Important Sequel, not the Usual Kind, in a Hot Genomics ETF

KraneShares MSCI All China Health Care Index ETF

Invesco DWA Healthcare Momentum ETF

The best healthcare ETFs for Q4 2020 are ARKG, KURE, and PTH.

Best Healthcare ETFs for Q4 2020

Global X Genomics & Biotechnology ETF

Goldman Sachs ETF Trust - Goldman Sachs Motif Human Evolution ETF

Disruptive technology is always an interesting play for investors to consider and the genomics market is one to watch closely. According to the “Genomics Market – Growth, Trends, and Forecasts (2020-2025),” exponential growth in the space will occur within the next five years.

The Genomics Market is Poised for Growth Through 2025

ARK Web x.0 ETF

Global X Video Games & Esports ETF 

Proshares Online Retail ETF

Invesco Solar ETF

We highlight five ETFs from different sectors of the broad market that have outperformed and gained at least 50% so far this year.

5 Sector ETFs That Have Gained More Than 50% This Year

This year, some healthcare exchange traded funds are hot. Then there’s the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG), which is absolutely sizzling.

Compelling Reasons to Love ARK Genomics ETF ‘ARKG’

ARK Innovation ETF

JPMorgan Ultra-Short Income ETF

PIMCO Enhanced Short Maturity Active ETF

By Todd Rosenbluth, CFRA The active equity ETF universe is getting more crowded as more established mutual fund providers enter the market and the suite of Buffer ETFs, also known as defined outcome ETFs, become more prevalent. While equity ETFs represent 54% of the active ETF offerings available, this year equity funds make up 82% of [.

Making Room in the ARK for Other Equity ETFs

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

ALPS Medical Breakthroughs ETF

SPDR S&P Biotech ETF

Biotech ETFs are popular and delivering for investors, but not all of these funds need the Covid-19 pandemic to soar.

7 Biotech ETFs to Buy Now For Covid-19 And Beyond

VanEck Vectors Biotech ETF

iShares Nasdaq Biotechnology ETF

Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.

Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain

Global X Robotics & Artificial Intelligence ETF

First Trust NASDAQ Cybersecurity ETF

Global X Cloud Computing ETF

iShares Global Clean Energy ETF

Thematic ETFs let investors express their views in a more cost-efficient way "in a broader index-based world," industry analysts say.

Thematic ETFs are red-hot. Analysts assess the market's newest darlings

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is already at the center of a variety of disruptive, innovative healthcare ideas. One of the emerging concepts ARKG is levered to is precision medicine.

Precision Power Boosts Case for Genomics ETF

The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.

Biotech ETFs to Gain on Coronavirus Vaccine Progress

When it comes to health care exchange-traded funds in 2020, it's a case of haves and have nots.

It's One Of This Year's Best Health Care ETFs And It Doesn't Own Any Moderna

ProShares Ultra Nasdaq Biotechnology

iShares Genomics Immunology and Healthcare ETF

From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.

Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is already one of the best-performing healthcare ETFs over the past several years, but with a slew of secular tailwinds behind the genomics industry, ARKG’s best days could be ahead. Genomics companies try to better understand how biological information is collected, processed, and applied by reducing guesswork [.

Genomics Long-Term Trajectory Shines a Light on ARKG

With a global healthcare crisis leading to a worldwide financial crisis, investors are looking to disruptive companies that can benefit in times of uncertainty and volatility. These types of funds can be found in areas where the impact of Coronavirus corresponds to the solutions being developed by medical and tech-based companies.

ARK Invest: The Rise of the Importance of Virtual Care Amid Covid-19

Fidelity MSCI Health Care ETF

iShares U.S. Medical Devices ETF

Invesco S&P 500 Equal Weight Health Care ETF

SPDR S&P Health Care Equipment ETF

Between the novel coronavirus and an election year, these healthcare ETFs appear poised to post strong growth into 2021.

7 Healthcare ETFs Which Should Continue Growing Into 2021

As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.

Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen

ETF Trends CEO Tom Lydon discussed the ARK Genomic Revolution Multi-Sector Fund (ARKG) on this week’s “ETF of the Week” podcast with Chuck Jaffe on the MoneyLife Show. The ARK Genomic Revolution ETF (ARKG) is an actively-managed fund from the team at ARK Invest that tries to pick the companies best positioned to profit from advancements [.

ETF of the Week: ARK Genomic Revolution Multi-Sector Fund (ARKG)

MicroSectors FANG+ ETN

WisdomTree Cloud Computing Fund

We have highlighted four ETFs from various industries that were the star performers in the first half and are likely to continue their outperformance if the current trends continue.

4 Sector ETFs Up More Than 30% in First-Half 2020

Breakwave Dry Bulk Shipping ETF

US Global Jets ETF

United States Oil Fund LP

iPath S&P 500 VIX Short-Term Futures ETN Class A

Inside the best and worst performing ETFs of first half.

Top & Flop Zones of First-Half 2020 and Their ETFs

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) jumped 5.34% last week, run fueled by concerns of a second wave of the novel coronavirus and news that some of the ETFs components are making progress on the vaccine front. ARKG includes companies that merge healthcare with technology and capitalize on the revolution in genomic sequencing.

Coronavirus Flareup Sparked a Great Week for Active Genomics ETF

Inovio Pharmaceuticals

Biotechnology sector-related exchange traded funds were among the leaders on Tuesday after the Department of Defense provided funding to Inovio Pharmaceuticals (NasdaqGS: INO) to scale up manufacturing of a DNA vaccine for the novel coronavirus.

Biotech ETFs Rally After Inovio Locks in DOD Coronavirus Deal

Biotechnology sector-related exchange traded funds were among the leaders on Monday after Invitae Corp. (NYSE: NVTA) announced a $1.4 billion deal for ArcherDX, potentially bolstering the genetic information company’s offering lineup and growth outlook.

Biotech ETFs Surge After Invitae Acquires ArcherDX

An important though often overlooked trait of disruptive technologies is that many often intersect with each other. The healthcare sector is an epicenter of that intersection.

Two Disruptive ETFs for One Vital Theme

Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.

News for ARK Genomic Revolution Multi-Sector ETF ETF (ARKG)